Pharmacokinetics, safety and efficacy of atazanavir /dolutegravir/lamivudine regimen as maintenance regimen in patients with intolerance and/or resistance to NRTIs, NNRTIs and RTV: a pilot study (PRADA II study)

Trial Profile

Pharmacokinetics, safety and efficacy of atazanavir /dolutegravir/lamivudine regimen as maintenance regimen in patients with intolerance and/or resistance to NRTIs, NNRTIs and RTV: a pilot study (PRADA II study)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Atazanavir (Primary) ; Dolutegravir (Primary) ; Lamivudine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms PRADA II
  • Most Recent Events

    • 30 Mar 2017 Status changed from recruiting to discontinued due to introduction of another integrase inhibitor, recruitement was not feasible anymore.
    • 06 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 06 Apr 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top